These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34232650)

  • 1. Identification of a Series of
    Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
    Seal JT; Atkinson SJ; Aylott H; Bamborough P; Chung CW; Copley RCB; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Lindon M; Messenger C; Michon AM; Mitchell D; Preston A; Prinjha RK; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2020 Sep; 63(17):9093-9126. PubMed ID: 32702236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
    Aylott HE; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Seal JT; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Mar; 64(6):3249-3281. PubMed ID: 33662213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
    Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
    J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Discovery and Optimization of Furo[3,2-
    Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y
    J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
    Lucas SCC; Atkinson SJ; Chung CW; Davis R; Gordon L; Grandi P; Gray JJR; Grimes T; Phillipou A; Preston AG; Prinjha RK; Rioja I; Taylor S; Tomkinson NCO; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2021 Aug; 64(15):10711-10741. PubMed ID: 34260229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
    Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
    Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
    Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
    Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of a Highly Selective and
    Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
    Gilan O; Rioja I; Knezevic K; Bell MJ; Yeung MM; Harker NR; Lam EYN; Chung CW; Bamborough P; Petretich M; Urh M; Atkinson SJ; Bassil AK; Roberts EJ; Vassiliadis D; Burr ML; Preston AGS; Wellaway C; Werner T; Gray JR; Michon AM; Gobbetti T; Kumar V; Soden PE; Haynes A; Vappiani J; Tough DF; Taylor S; Dawson SJ; Bantscheff M; Lindon M; Drewes G; Demont EH; Daniels DL; Grandi P; Prinjha RK; Dawson MA
    Science; 2020 Apr; 368(6489):387-394. PubMed ID: 32193360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
    Seal JT; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Foley J; Gordon L; Grandi P; Gray JRJ; Harrison LA; Kruger RG; Matteo JJ; McCabe MT; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Wyce A; Zhang XP; Demont EH
    J Med Chem; 2021 Aug; 64(15):10772-10805. PubMed ID: 34255512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
    Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
    Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
    Liang D; Yu Y; Ma Z
    Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.